People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| 858 Therapeutics, Inc. | — | Pharmaceuticals | Series B | $65.2M | $177.2M | 2024 |
Katherine Bell-McGuinn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Katherine Bell-McGuinn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ali Behbahani | 1 | 17 |
| Clare Ozawa | 1 | 8 |
| Carlo Rizzuto | 1 | 7 |
| Bradley J. Bolzon | 1 | 5 |
| Stafford Jeffrey | 1 | 1 |
| Ali A. Behbahani | 1 | 1 |
| Jeffrey A. Stafford | 1 | 1 |
| Clare J. Ozawa | 1 | 1 |
| James J. Veal | 1 | 1 |
| James Veal | 1 | 1 |
| Jane Huang | 1 | 1 |
| Monal Mehta | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.